The effect of antiangiogenic agent aflibercept on surgically induced endometriosis in a rat model
article
OA: diamond
CC0
⤵ 1 in-corpus citation
AI-generated summary
Aflibercept significantly reduced endometriosis lesion volume, improved adhesions, and decreased VEGF-H and CD31 expression compared to leuprolide acetate in a rat model.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Objective:The aim of the study is to show for the first time how aflibercept affects endometriosis lesions.Material and methods: Surgically induced endometriosis in Wistar albino female rats.Rats with endometriosis were randomly divided into three groups: control (Co), aflibercept (Af), and leuprolide acetate (Le).Then, Af, aflibercept, and Le received leuprolide acetate.The control group was not treated.The weights and changes in intra-abdominal adhesions of the rats before and after treatment were recorded according to the Blauer adhesion score.Blood extracted for sacrifice was analyzed.Endometriotic lesions were evaluated for size, volume, histology, and immunohistochemistry (vascular endothelial growth factor [VEGF] and CD31).Significance level was accepted as p < 0.05.Results: Aflibercept significantly reduced endometrial implant volume (p = 0.002).The explant epithelial histological score showed a significant difference between aflibercept and leuprolide acetate (p = 0.006) and between aflibercept and control groups (p = 0.002).Aflibercept decreased VEGF-H and CD31 expression (p = 0.001) more than leuprolide acetate.Aflibercept improved adhesions (p = 0.006).Conclusion: Aflibercept is more successful than leuprolide acetate in the treatment of endometriosis.
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (26)
- Angiogenesis lymphangiogenesis and neurogenesis in endometriosis via openalex
- A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model via openalex
- Effects of ranibizumab and zoledronic acid on endometriosis in a rat model via openalex
- Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets—a narrative review via openalex
- Endometriosis in the Mouse: Challenges and Progress Toward a ‘Best Fit’ Murine Model via openalex
- Experimental Endometriosis: Review of the Literature Through a Century and the Iranian Experience. via openalex
- Is montelukast effective in regression of endometrial implants in an experimentally induced endometriosis model in rats? via openalex
- Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review via openalex
- Quality of life in women with endometriosis: a narrative overview via openalex
- Rosiglitazone affects the progression of surgically‑induced endometriosis in a rat model via openalex
- The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres via openalex
- The Effects of Micronized Progesterone and Cabergoline On a Rat Autotransplantation Endometriosis Model: A Placebo Controlled Randomized Trial via openalex
- The effects of thalidomide in a rat model of surgically-induced endometriosis via openalex
- The Efficacy of Bevacizumab, Sorafenib, and Retinoic Acid on Rat Endometriosis Model via openalex
- W4245611694 via openalex
- W1971586374 via openalex
- W2040973546 via openalex
- W2067380467 via openalex
- W2069702442 via openalex
- W2110225766 via openalex
- W2140246703 via openalex
- W2171127905 via openalex
- W2209507541 via openalex
- W2337737811 via openalex
- W2346020725 via openalex
- W3161227226 via openalex
Cited by (1)
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK